Recent

% | $
Quotes you view appear here for quick access.

aTyr Pharma Inc. Message Board

momentum74 9 posts  |  Last Activity: Jun 28, 2016 1:01 AM Member since: Feb 28, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ENDP very oversold value stock. Futures are up in the ah it should have a nice bounce on the news imo.Edition: United States
    TOP NEWS
    BUSINESS
    MARKETS
    WORLD
    POLITICS
    TECHNOLOGY
    COMMENTARY
    MONEY
    LIFE
    PICTURES
    VIDEO
    TOP NEWS
    Mon Jun 27, 2016 | 5:48 PM EDT
    Exclusive: Specialty drugmaker Endo explores asset sales - sources

    X
    By Carl O'Donnell and Greg Roumeliotis
    (Reuters) - Specialty pharmaceutical company Endo International Plc (ENDP.O) has held discussions with private equity firms about potential asset sales as it seeks to reduce its more than $8 billion debt pile, according to people familiar with the matter.

    The move underscores the challenges facing the Dublin-based company, which has seen its shares drop 77 percent this year amid investor concerns that downward pressure on drug prices could upend its acquisition-driven business model.

    Endo, which has a market capitalization of $3 billion, has been exploring several options, including an asset swap with another company, one of the people said. The discussions are at an early stage and no transaction may occur, the people cautioned.

    The sources asked not to be identified because the deliberations are confidential. Endo declined to comment.

    Endo offers a suite of specialty, generic and over-the-counter medical products spanning therapeutic areas including pain, urology and endocrinology.

    The company cut its 2016 earnings guidance in May, fuelling concerns about mounting pressure on its drug prices from payers and regulators.

    ADVERTISEMENT
    Advertisement
    In April, Reuters reported that another major acquisitive specialty pharmaceutical company, Valeant Pharmaceuticals International Plc (VRX.TO), was also reviewing asset sales as it too struggled with high debt and downward pressure on its drug prices.

    Valeant became a poster child for perceived flaws in the business model of specialty pharmaceutical companies, as it came under intense scrutiny from politicians and regulators for its reliance on acquisitions a

  • HHS is extremely oversold and undervalued imo. Stock should have a nice run after this news.

    Harte Hanks Seeks Strategic Alternatives for Trillium Software The Board of Directors has engaged Foros to advise Harte Hanks during this process. There can be no assurance the Company's review of strategic alternatives will result in any transaction. The Company does not intend to make further public comment regarding these matters during the strategic review and exploration process.

    In closing, Puckett commented, "These steps, along with our acquisitions of a digital search management company and marketing consulting firm, will allow us to focus and take advantage of the growth opportunity with our Customer Interaction business to serve chief marketing officers with a unique combination of strategy, marketing, analytics, and marketing execution capabilities."

    Sentiment: Strong Buy

  • Reply to

    DNAI 6.05 prior completed studies bullish.

    by momentum74 May 25, 2016 11:46 AM
    momentum74 momentum74 May 25, 2016 11:50 AM Flag

    11 patients achieving a complete response (CR), partial response (PR) or stable disease (SD). Furthermore, all four of the diffuse large B-cell lymphoma (DLBCL) patients treated in this trial experienced a clinical response, including three CRs and one PR, with reported durations on study in the range of nine to more than 20 months.

    For more information, please go to Clinicaltrials bullish

    Sentiment: Strong Buy

  • Go to pronai site for more info.

    Completed studies

    We have conducted two clinical trials with single-agent PNT2258 to date: a Phase 1 safety trial in 22 patients with relapsed or refractory solid tumors and a Phase 2 trial in 13 patients with relapsed or refractory NHL.

    Phase 1 dose escalation clinical trial

    We initiated our Phase 1 dose escalation clinical trial with PNT2258 in 2010 to determine the safety and tolerability of PNT2258 administered by intravenous infusion. This Phase 1 trial involved 22 patients with relapsed or refractory solid tumor malignancies, including patients diagnosed with non-small cell lung cancer, squamous cell cancer of the head and neck, colorectal cancer, breast cancer, endometrial cancer, liver cancer, pancreatic cancer and prostate cancer. As this trial was safety oriented, patients were not chosen for participation on the basis of their BCL2 status and, thus, overt evidence of anti-tumor effect was not expected. PNT2

    258 was considered to be well tolerated at all doses by the investigators in this trial. In addition, there was no evidence of a systemic immune response to the LNP or PNT100; no significant changes in immune-stimulatory cytokines or clinical signs of anap8hylaxis following dosing of PNT2258 were observed, which supports the lack of a non-specific immune response.

    For more information, please go to Clinicaltrials.gov.

    Phase 2 trial in relapsed or refractory NHL

    In December 2012, we initiated a single arm, open-label Phase 2 trial in patients with relapsed or refractory NHL, defined as patients who are no longer or were never responsive to treatment with approved or experimental therapies. The primary objective was to determine PNT2258’s anti-tumor activity across several hematological malignancies and to collect safety data.

    In this trial, which enrolled 13 patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), PNT2258 demonstrated evidence of anti-tumor activity, with 11

    Sentiment: Strong Buy

  • Hopefully they are continuing to buy this quarter as well. Volume has been strong for about a week now. Long for a swing bounce trade. source whalewisdom

    Sentiment: Strong Buy

  • Sheff is one of the best biotech traders around. Volume is starting to surge.

    Pasted.
    New Economy Portfolio Update..Entered that has a big Oral presentation at ASCO 16 on June 6th. 52wk low is $4.48 & 52wk high is $33.75. Lots of upside here.

    Alert..entered $DNAI at $5.26 (10%) in the New Economy Portfolio. 300K shares have traded with 45m left in the trading day. This should continue to move higher into & thru ASCO.

    Sentiment: Strong Buy

  • VANCOUVER, May 18, 2016 /PRNewswire/ - ProNAi Therapeutics, Inc. (DNAI), a clinical-stage oncology company advancing novel targeted therapeutics for patients with cancer, today announced it will present interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) on June 6th at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).

    Sentiment: Strong Buy

  • Looks like the move into the June results could be starting. There is also an annual shareholders meeting coming in June. The average daily volume is starting to increase. Best of luck to all traders and investors. Long at 5.32 for swing bounce-trade.

    Sentiment: Strong Buy

  • Stock trading near cash was down 11 days in a row until today. Very oversold technically , looking for a nice rally. My average price is 5.32 .

    Sentiment: Strong Buy

LIFE
3.41+0.44(+14.81%)Jul 29 4:00 PMEDT